The comparative study of the effects of miglitol and voglibose (alpha-glucosidase inhibitors) on incretins secretio
- Conditions
- type-2 diabetes
- Registration Number
- JPRN-UMIN000001671
- Lead Sponsor
- Akita University School of Medicine Department of Endocrinology, Diabetes and Geriatric Medicine
- Brief Summary
To compare the effects of miglitol [an alpha-glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12-week administration of both drugs, during 2-h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP-1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP-1. In conclusion, both drugs can enhance postprandial GLP-1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP-reducing efficacy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1) type-1 diabetes 2) severe hepatic or renal disease 3) severe heart disease 4) having canceres 5) unstable diabetic retinpathy 6) having a condyion to be worsened by increase in intestinal gas 7) a woman who is nursing or pregnant 8) after gstrectomy 9) a patient who is judged as not appropriate for participation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Coparisons of changes in plasma glucose, insulin, GLP-1 and GIP in response to a mixed meal before and after administration of miglitol or voglibose.
- Secondary Outcome Measures
Name Time Method HbA1c, body weight, BMI, serum levels of adiponectin, high-sense CRP and MCP-1 at baseline and 3 month aftrer administrations of miglitol or voglibose.